# Glioblastoma

4 related articles

Subscribe to updates

Lantern Pharma Nov 10, 2026
LP-184 Phase 1a data in recurrent glioblastoma published: recommended dose set, spironolactone combination heads to Phase 1b/2a
Lantern Pharma reported Phase 1a data for LP-184 (zirdafulven) in recurrent glioblastoma and set an expansion dose of 0.39 mg/kg. Because only about 20% of systemic drug is expected to reach brain tumors, single-agent brain concentrations are not projected to stay at therapeutic levels, so the company plans a Phase 1b/2a trial combining LP-184 with spironolactone, which degrades the DNA repair protein ERCC3. In preclinical models, spironolactone lowered the LP-184 concentration needed to kill tumor cells 3- to 6-fold.
Lantern Pharma reported Phase 1a data for LP-184 (zirdafulven) in recurrent glioblastoma and set an expansion dose of 0.39 mg/kg. Because only about 20% of systemic drug is expected to reach brain tumors, single-agent brain concentrations are not projected to stay at therapeutic levels, so the company plans a Phase 1b/2a trial combining LP-184 with spironolactone, which degrades the DNA repair protein ERCC3. In preclinical models, spironolactone lowered the LP-184 concentration needed to kill tumor cells 3- to 6-fold.
Lantern Pharma Johns Hopkins University
LP-184 Glioblastoma LP-184 plus spironolactone combination Phase 1a clinical trial
Nature Nov 4, 2026
Glioblastoma's malignant states are not scattered at random: a developmental-to-injury-and-hypoxia trajectory layers around the necrotic core
Glioblastoma malignant states were treated as parallel subtypes, and a single biopsy could not represent the whole tumour. Pairing single-nucleus and spatial transcriptomics across 12 IDH-wild-type primary tumours and 57 sampling sites revealed a trajectory from developmental-like states toward glial injury response and hypoxia, layered in space from the infiltrating edge to the necrotic core; the trajectory appears across tumour subtypes and genetically distinct subclones and is recapitulated in patient-derived organoids.
Glioblastoma malignant states were treated as parallel subtypes, and a single biopsy could not represent the whole tumour. Pairing single-nucleus and spatial transcriptomics across 12 IDH-wild-type primary tumours and 57 sampling sites revealed a trajectory from developmental-like states toward glial injury response and hypoxia, layered in space from the infiltrating edge to the necrotic core; the trajectory appears across tumour subtypes and genetically distinct subclones and is recapitulated in patient-derived organoids.
University Hospital Heidelberg University of Cambridge Central Institute of Mental Health Medizinische Fakultät Mannheim Istanbul Medipol University Heidelberg University European Molecular Biology Laboratory Cambridge University Hospitals NHS Foundation Trust
Grant de Jong（First author）Grant de Jong（First author）
Glioblastoma SpaceTree Intratumor Heterogeneity Spatial transcriptomics RNA Velocity
Nature Communications Nov 2, 2026
Glioblastoma invasion gets a live-brain-slice tracker: thousands of cells followed as standard therapy enriches the fastest branching state
Glioblastoma cells switch among branching, diffuse translocation, locomotion and perivascular invasion modes, but these switches were hard to observe at scale over days in intact brain tissue. GlioTrace links whole-specimen confocal imaging, convolutional-network morphology classification and a covariate hidden Markov model to track thousands of cells across six patient-derived xenograft brain slices. Invasion plasticity proved patient-specific and spatially organized, modulated by vascular proximity and microglial contact; targeted drugs shifted phenotype composition and transition probabilities, while radiation plus temozolomide enriched the fastest, highly connected branching state.
Glioblastoma cells switch among branching, diffuse translocation, locomotion and perivascular invasion modes, but these switches were hard to observe at scale over days in intact brain tissue. GlioTrace links whole-specimen confocal imaging, convolutional-network morphology classification and a covariate hidden Markov model to track thousands of cells across six patient-derived xenograft brain slices. Invasion plasticity proved patient-specific and spatially organized, modulated by vascular proximity and microglial contact; targeted drugs shifted phenotype composition and transition probabilities, while radiation plus temozolomide enriched the fastest, highly connected branching state.
University of Gothenburg Chalmers University of Technology Uppsala University
Hitesh Bhagavanbhai Mangukiya（First author）Sven Nelander（Corresponding author）
GlioTrace Covariate Hidden Markov Model Convolutional Neural Network Glioblastoma Single-Cell RNA Sequencing
Trends in biotechnology Sep 16, 2026
Liquid biopsy in glioblastoma: emerging technologies and translational opportunities
This review focuses on liquid biopsy for glioblastoma, noting that tissue biopsy is invasive and fails to capture tumor heterogeneity or temporal dynamics, while liquid biopsy can provide noninvasive real-time monitoring via circulating biomarkers such as cell-free DNA, circulating tumor DNA, circulating tumor cells, and extracellular vesicles in plasma, cerebrospinal fluid, urine, and saliva; it advances beyond prior biomarker catalogs by delivering a quantitative technology scorecard comparing cfDNA-, CTC-, and EV-based platforms in terms of sensitivity, clinical actionability, cost, and scalability, and introduces a multimodal decision matrix and an AI-driven fusion pipeline integrating fragmentomics, EV proteomics, and CTC transcriptomics to enhance minimal residual disease detection a
This review focuses on liquid biopsy for glioblastoma, noting that tissue biopsy is invasive and fails to capture tumor heterogeneity or temporal dynamics, while liquid biopsy can provide noninvasive real-time monitoring via circulating biomarkers such as cell-free DNA, circulating tumor DNA, circulating tumor cells, and extracellular vesicles in plasma, cerebrospinal fluid, urine, and saliva; it advances beyond prior biomarker catalogs by delivering a quantitative technology scorecard comparing cfDNA-, CTC-, and EV-based platforms in terms of sensitivity, clinical actionability, cost, and scalability, and introduces a multimodal decision matrix and an AI-driven fusion pipeline integrating fragmentomics, EV proteomics, and CTC transcriptomics to enhance minimal residual disease detection a
Rambam Health Care Campus Reichman University Bar-Ilan University
Olawumi Giwa（First author）
Liquid biopsy Glioblastoma Circulating tumor DNA Circulating tumor cells Extracellular vesicles

You’re all caught up

LP-184 Phase 1a data in recurrent glioblastoma published: recommended dose set, spironolactone combination heads to Phase 1b/2a

Glioblastoma's malignant states are not scattered at random: a developmental-to-injury-and-hypoxia trajectory layers around the necrotic core

Glioblastoma invasion gets a live-brain-slice tracker: thousands of cells followed as standard therapy enriches the fastest branching state

Liquid biopsy in glioblastoma: emerging technologies and translational opportunities